AGWCA
INKT icon

Annis Gardner Whiting Capital Advisors’s MiNK Therapeutics INKT Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.11K Buy
+200
New +$2.23K ﹤0.01% 1050

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's INKT Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors opened a new position in MiNK Therapeutics (INKT) in Q1 2026: 200 shares worth $2.11K. The stake represents ﹤0.01% of the portfolio and ranks #1050 among its holdings.

23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Annis Gardner Whiting Capital Advisors held 200 shares of MiNK Therapeutics worth $2.11K as of Q1 2026.
  • MiNK Therapeutics was a new Annis Gardner Whiting Capital Advisors position in Q1 2026.
  • MiNK Therapeutics made up ﹤0.01% of Annis Gardner Whiting Capital Advisors's portfolio in Q1 2026, its #1050 holding.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.